BridgeMD
Tests treatment safety and results for Relapsed or Refractory T Cell Lymphoma and Chronic...
Official title A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
ClinicalTrials.gov ID: NCT06547528
What this study is testing
What is ONO-4685?
ONO-4685 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for relapsed or refractory t cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with histopathologically confirmed diagnosis of one of the following subtypes as defined by the 2017 revision of the WHO classification of...
- Angioimmunoblastic T-cell lymphoma(AITL)
- Peripheral T-cell lymphoma, NOS(PTCL-NOS)
- Nodal peripheral T-cell lymphoma with TFH phenotype(nodal PTCL with TFH)
- Follicular T-cell lymphoma(FTCL) Cutaneous T-cell lymphoma(CTCL)
You likely can't join if
- Patients with severe complications.
- Patients with multiple cancers.
See the full eligibility criteria
- Patients with histopathologically confirmed diagnosis of one of the following subtypes as defined by the 2017 revision of the WHO classification of lymphoid malignancies: Peripheral T-cell lymphoma(PTCL)
- Angioimmunoblastic T-cell lymphoma(AITL)
- Peripheral T-cell lymphoma, NOS(PTCL-NOS)
- Nodal peripheral T-cell lymphoma with TFH phenotype(nodal PTCL with TFH)
- Follicular T-cell lymphoma(FTCL) Cutaneous T-cell lymphoma(CTCL)
- Mycosis fungoides(MF)
- Sezary syndrome Chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL)
- Relapsed or refractory patients with tumors for which no established standard therapy is available, or refractory or intolerant to existing standard therapy judged by principal investigator or subinvestigator
- ECOG PS 0\~2
- Life expectancy of at least 3 months
- Patients with severe complications.
- Patients with multiple cancers.
The study team makes the final eligibility decision.
Where it's taking place
- Nagoya, Aichi-ken, Japan
- Akita, Akita, Japan
- Kashiwa-shi, Chiba, Japan
- Fukuoka, Fukuoka, Japan
- Sapporo, Hokkaido, Japan
- Isehara-shi, Kanagawa, Japan
- Kumamoto, Kumamoto, Japan
- Kyoto, Kyoto, Japan
- Sendai, Miyagi, Japan
- Okayama, Okayama-ken, Japan
- Osaka Sayama-shi, Osaka, Japan
- Osaka-fu, Osaka, Japan
- Koto-ku, Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nagoya, Aichi-ken, Japan; Akita, Akita, Japan; Kashiwa-shi, Chiba, Japan; Fukuoka, Fukuoka, Japan; Sapporo, Hokkaido, Japan; Isehara-shi, Kanagawa, Japan and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.